NCT04118062Befejeződött
Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR)
Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. A Qualitative Cross-sectional Study of Professionals, Patients, Parents of Sick Children, and Expert Patients, in the Context of Triple Negative or Luminal B Breast Cancer, Metastatic Uveal Melanoma and Pediatric Cancers.
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2025. szept. 19.
Rövid összefoglaló (regiszter, angolul)
Resistance to treatment is one of the major themes in cancer research. Despite this, the definition and clinical implications of resistance to treatment remain under-explored, and patient-physician communication in this context still constitutes a challenge. When resistance to cancer treatments occurs, physicians not only have to explain to the patient the phenomenon of resistance, often based on complex results (biological results, genomic tests, imaging, etc.), but also need to offer alternative therapies, whilst fostering shared medical decision-making. These different tasks are particularly challenging for clinicians, especially since there are large individual differences at patient level. Indeed, each patient has his or her own unique information needs, capacity for understanding, and level of desire to participate in treatment decisions.
- Állapot (regiszter)
- Befejeződött
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 128 (tényleges)
- Első benyújtás
- 2019. szept. 11.
- Kezdés
- 2021. febr. 2.
- Elsődleges befejezés
- 2023. máj. 26.
- Fő szponzor
- Institut Curie
- Betegségek
- Melanóma, Áttétes emlőrák, Tripla negatív emlőrák
- NCT-szám
- NCT04118062
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó
- Bevont résztvevők: 128
- 2021. febr. 2. és az elsődleges befejezés (2023. máj. 26.) között
- 1 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Más betegség
- Patients \& parents of a sick child:
- To have difficulties in understanding the French language.
- Have or have had cancer (criteria only for parents);
- Pregnant woman, likely to be pregnant or breastfeeding (criteria only for patients).
- Persons deprived of their liberty or under guardianship;
- Impossibility of study requirements respect for geographical, social or psychological reasons.
Egyéb
- Expert patients:
- To have difficulties in understanding the French language ;
- Currently being undergoing anti-tumor treatment.
- Professionals:
- To have difficulties in understanding the French language ;
- Not to be confronted in professional practice with resistance to anti-tumor treatments.
Kiket keres a vizsgálat
- Patients:
- To be 18 years of age or older ;
- To have metastatic uveal melanoma (MUM) or triple negative or luminal B breast cancer ;
- To have received the information that the disease is resistant to treatment ;
- To have read the information and signed the informed consent.
- Parents of a sick child:
- To be a parent (parental authority holder) of a child with cancer ;
- To have received the information that the child disease is resistant to treatment ;
- To have read the information and signed the informed consent.
- Expert patients:
- To be 18 years of age or older ;
- To have had cancer (regardless the cancer site) ;
- To participated to an expert patient training (fine knowledge of the illness, experience with the disease) ;
- To have read the information and signed the informed consent.
- Professionals:
- To be an oncologist (medical oncologist, surgeon, radiotherapist, supportive care specialist) and/or to be a researcher in oncology (doctor, biologist, geneticist ...) ;
- To have patients with a triple-negative or luminal B breast cancer or metastatic uveal melanoma which is resistant to anti-tumor treatments and/or to take part to a research on resistance to cancer treatment;
- To have read the information and signed the informed consent.
Életkor a regiszterben: 18 év – - · Nem: nők és férfiak · Egészséges önkénteseket nem fogad
Helyszínek (1)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| Institut Curie | Paris | Franciaország | Ismeretlen állapot |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.